Advertisement
"We are pleased that shares of our common stock are now being quoted bothon the OTC Bulletin Board and the Pink Sheets," said Barbara Duncan, ChiefExecutive Officer of DOV. "We believe this dual quotation on the OTC BulletinBoard and the Pink Sheets provides the Company with greater visibility in theinvestment community and offers our shareholders, both current and future,greater liquidity."
Advertisement
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisitionand development of novel drug candidates for central nervous system disorders.The Company's product candidates address some of the largest pharmaceuticalmarkets in the world including depression, pain and insomnia.
Cautionary Note
Statements in this press release that are not historical facts constituteforward-looking statements within the meaning of Section 27A of the SecuritiesAct of 1933 and Section 21E of the Securities Exchange Act of 1934, each asamended. You can also identify forward-looking statements by the followingwords: may, will, should, expect, intend, plan, anticipate, believe, estimate,predict, potential, continue or the negative of these terms or othercomparable terminology. We caution you that forward-looking statements areinherently uncertain and are simply point-in-time estimates based on acombination of facts and factors currently known by us about which we cannotbe certain or even relatively confident. Actual results or events will surelydiffer and may differ materially from our forward-looking statements as aresult of many factors, some of which we may not be able to predict or may notbe within our control. Such factors may also materially adversely affect ourability to achieve our objectives and to successfully develop andcommercialize our product candidates, including our ability to:
You should also refer to the risks discussed in our filings with theSecurities and Exchange Commission including those contained in our AnnualReport on Form 10-K for the fiscal year ended December 31, 2006 that was filedon March 30, 2007 and our Quarterly Report on Form 10-Q for the quarter endedJune 30, 2007 that was filed on August 8, 2007. We qualify all our forward-looking statements by these cautionary statements. Readers should not placeundue reliance on our forward-looking statements. We do not undertake anyobligation and do not intend to update any forward-looking statement.-- raise substantial additional capital in order to fund operations; -- obtain and maintain all necessary patents, licenses and other intellectual property rights; -- demonstrate the safety and efficacy of product candidates at each stage of development; -- meet our development schedule for our product candidates, including with respect to clinical trial initiation, enrollment and completion; -- meet applicable regulatory standards and receive required regulatory approvals on our anticipated time schedule or at all; -- meet or require our partners to meet obligations and achieve milestones under our license and other agreements; -- maintain collaborations as required with pharmaceutical partners; -- seek and evaluate strategic alternatives, including with respect to collaborations and partnerships for certain of our development programs and compounds; and -- produce drug candidates in commercial quantities at reasonable costs and compete successfully against other products and companies.
SOURCE DOV Pharmaceutical, Inc.
